Wellness Unmasked Weekly Rundown: Weight Loss Drugs Truth Bomb & Meningitis Scare

Are weight loss drugs really the breakthrough they’re being sold as—or is there a hidden catch?

On this episode of Wellness Unmasked, Dr. Nicole Saphier breaks down two major health stories making headlines—and what they reveal about the state of modern medicine.

First, a meningitis B outbreak in the UK raises serious concerns about vaccine awareness, public health response, and why college students remain at higher risk. Dr. Saphier explains what’s actually happening, why early intervention matters, and what Americans should be watching for next.

Then, a deep dive into the exploding popularity of GLP-1 weight loss drugs like semaglutide and tirzepatide. While these medications are delivering dramatic results, new research shows what happens when patients stop taking them—and it’s not good. From rapid weight regain to declining heart health, the long-term reality may be far more complicated than advertised.

In this episode:

• The truth about meningitis outbreaks and who’s most at risk
• Why vaccine decisions are becoming more individualized
• The real benefits—and risks—of GLP-1 weight loss drugs
• What happens to your body after stopping these medications
• Why sustainable health still comes down to lifestyle, not shortcuts

If you’re trying to make smarter decisions about your health in a world full of quick fixes and conflicting advice, this episode is essential listening.

See omnystudio.com/listener for privacy information.

Episode Transcript

Speaker 1 (00:02):
Welcome to Wellness un Mass. I'm doctor Nicole Safire and
this is your weekly rundown. Now, let's catch up on
what's happening this week, because there are two stories that,
while they seem totally unrelated, they actually say a lot
about how we're approaching medicine right now. Let's start with
the UK. I mentioned it last week. I talked about
that there was a slight uptick in meningitis B cases,

(00:23):
specifically in an area of Kent, mostly affecting university students,
and it definitely raised some concern. Here's a good news.
Cases are now starting to come down. We've gone from
mid thirty cases to about twenty confirmed after further testing,
So they actually thought they had more cases than they
really did. That's good news. Now. That might not sound

(00:45):
too dramatic that they said that there were thirty cases
and there were twenty cases, but in infectious disease, that
shift it absolutely matters, and it means that response is
also working too. Because of the confirmed cases. They aren't
seeing new cases or more cases because public health officials
they move quickly, getting the antibiotics, making sure they were

(01:05):
diagnosing it, getting close contacts. Yeah, I remember contact tracing
with COVID even more important, well that wasn't even that
important at all with COVID, but definitely important when it
comes to meningitis. They also increase their vaccination campaigns. We
were talking about the meningitis vaccine here in the United
States at the CDC ASIP meeting last year. It caused

(01:27):
a bit of an uproar because instead of mandating it
or putting it on the formal recommendations in kids going
off to college, they said they really wanted to be
a conversation with the doctor and risk based. Well, meningitis
is the most lethal in infants, but the vaccine is
not improved for infants, so obviously you're not going to
recommend it for infants. But it's the second highest risk

(01:51):
is kids, specifically like older adolescents, college aides, kids who
are all congregating together in dorm rooms. That's why there's
a recommendation for that vaccine to be given before kids
are going to college, especially especially especially if they are
living in the dorms or they are living in apartments
with other kids. Meningitis is no joke. It is not

(02:12):
a common cold. It is not like the flu. It
is very serious and should be taken seriously happy to
hear what's going on in the UK, and really hope
that we don't see any upticks come late summer here
in the United States because fewer people are getting vaccines.
That is definitely the trend that is happening here and

(02:33):
not just here, is happening across the world as well. Okay,
let's shift gears because the second story is a different
kind of health of shoe, but not surprising one we're
dealing with every day here in the United States. GLP
one medications, you know, the weight loss medications, Wagovi, Njaro,
all whatever the other name brands are that people are taking.

(02:54):
You know, these drugs, you know the other the actual
names are like semi glue, Tide, Truzeppetide. They've really changed
the conversation around weight loss and metabolic health in general.
And to be clear, they work. They absolutely work. I
think we all know that. All you have to do
is turn on the TV and all of a sudden,
Hollywood they've always been skinny, they're just even skinnier now.
But it's not just people in Hollywood. Everyone's on them

(03:17):
and you see it. You kind of see the wasting
away of the phases and yeah, I mean a lot
of people are losing weight. It is helping to tackle
the obesity crisis. Do they have side effects, Absolutely, they
have side effects. I think we don't talk about the
side effects enough. But the reality is there are benefits
to these medications, not only just losing weight, but all
the benefits that come with losing weight. One specifically has

(03:40):
been heart health, and this is well documented. People who
are on these medications and are losing weight, they have
decreased heart attacks and strokes and just overall better heart health. Well,
I hate to burst your bubble, people, but just like
I have told you, most of these medications, for most people,
you have to stay on them forever. Because the majority

(04:00):
of people over half I think it's even two thirds,
I don't know what the actual number is now. But
when people stop the medication, oftentimes they gain the weight back.
Some people gain the exact same amount of weight back.
Some people gain even more weight than when they started
out to begin Well, this new study raises an important

(04:22):
question or kind of answers it for us, what happens
to all of those help benefits when you stop the medication. Well,
the answer is it's not great. What researchers are seeing
is that many of those cardiovascular benefits they fade, and
they fade fairly quickly. Within about six months in this
one study, the risk factors for heart disease started creeping

(04:43):
back up. By a year, more significant changes are happening,
and by eighteen months of stopping the medication, all the
benefit of being on those medications they're gone. Some experts
are even calling it kind of like a medical whiplash,
and that is not healthy for your body, because now
you're putting your body in a state of struck. You're
shocking it by depleting its nutrients, and then you're shocking

(05:05):
it again by taking the medication away and adding all
the weight law or adding all the weight back. And
so I think this is where we need to pause
and be honest about what these medications are and what
they aren't. They're not a quick fix. They're not something
you can take for a few months and move on,
and for many patients they're looking more like long term,
possibly probably lifelong therapies, and that comes with real considerations cost.

(05:28):
They're expensive. You can get some I believe, on trump
Orex for a lower cost, but there's still expensive access,
who can get them, and then staying on the medication
and what happens if you can't, especially as we start
talking about using these drugs in younger people. That's right.
There are clinical trials for kids under the age of
ten taking these medications. It's already approved for teens and preteens.

(05:52):
I mean, that's crazy. We need to be teaching these
kids good, healthy lifestyle behaviors and not necessarily giving them medications.
Need to make sure that they have long term success. Yes,
they can be incredibly helpful, but they don't replace the
foundation of health, nutrition, physical activity and addressing underlying metabolic issues.

(06:12):
That's the answer. Those things still matter and they matter
long term. Thank you so much for listening to this
week's rundown. I'm doctor Nicole Saffire. Listen to Wellness on
mass on, iHeartRadio, Apple Podcasts, or wherever you get your podcasts.